Cargando…
Immune biological rationales for the design of combined radio- and immunotherapies
Cancer immunotherapies are promising treatments for many forms of cancer. Nevertheless, the response rates to, e.g., immune checkpoint inhibitors (ICI), are still in low double-digit percentage. This calls for further therapy optimization that should take into account combination of immunotherapies...
Autores principales: | Hader, Michael, Frey, Benjamin, Fietkau, Rainer, Hecht, Markus, Gaipl, Udo S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000501/ https://www.ncbi.nlm.nih.gov/pubmed/31953578 http://dx.doi.org/10.1007/s00262-019-02460-3 |
Ejemplares similares
-
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications
por: Derer, Anja, et al.
Publicado: (2015) -
Opportunities for immunotherapy in microsatellite instable colorectal cancer
por: Westdorp, Harm, et al.
Publicado: (2016) -
Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells
por: Wimmer, Sebastian, et al.
Publicado: (2021) -
4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016) -
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
por: Rojas-Sepúlveda, Daniel, et al.
Publicado: (2018)